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ABSTRACT
Objective To explore the impact of severity and manage-
ment (expectant, laser treatment or selective reduction)
on perinatal outcome of monochorionic twin pregnancies
complicated by selective fetal growth restriction (sFGR).
Methods MEDLINE, EMBASE, CINAHL, Clinical
Trials.gov and The Cochrane Library databases were
searched for studies on outcome following expectant
management, laser treatment or selective reduction in
monochorionic twin pregnancies complicated by sFGR.
Only pregnancies affected by sFGR and categorized
according to the Gratacós classification (Type I, II or
III) were included. The primary outcome was mortality,
including single and double intrauterine (IUD), neonatal
(NND) and perinatal deaths. Secondary outcomes were
neonatal morbidity, abnormal postnatal brain imaging,
intraventricular hemorrhage, periventricular leukomala-
cia, respiratory distress syndrome, admission to neonatal
intensive care unit and survival free from neurological
complications (intact survival). Meta-analyses of propor-
tions were used to analyze the extracted data according
to management, severity of sFGR and fetal size (smaller
vs larger twin).
Results Sixteen observational studies (786 monochori-
onic twin pregnancies) were included. In pregnancies
complicated by Type-I sFGR managed expectantly, IUD
occurred in 3.1% (95% CI, 1.1–5.9%) of fetuses and
97.9% (95% CI, 93.6–99.9%) of twins had intact
survival. In pregnancies complicated by Type-I sFGR
treated using laser therapy, IUD occurred in 16.7%
(95% CI, 0.4–64.1%) of fetuses and, in those treated
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using selective reduction, IUD occurred in 0% (95%
CI, 0–34.9%) of cotwins, with no evidence of neuro-
logical complications in the survivors. In pregnancies
complicated by Type-II sFGR managed expectantly, IUD
occurred in 16.6% (95% CI, 6.9–29.5%) and NND in
6.4% (95% CI, 0.2–28.2%) of fetuses, and 89.3% (95%
CI, 71.8–97.7%) of twins survived without neurolog-
ical compromise. In Type-II sFGR pregnancies treated
using laser therapy, IUD occurred in 44.3% (95% CI,
22.2–67.7%) of fetuses, while none of the affected
cases experienced morbidity and survivors were free of
neurological complications. Of pregnancies undergoing
selective reduction, IUD of the cotwin occurred in 5.0%
(95% CI, 0.03–20.5%) and NND in 3.7% (95% CI,
0.2–11.1%), and 90.6% (95% CI, 42.3–94.3%) of
surviving cotwins were free from neurological compli-
cations. In pregnancies complicated by Type-III sFGR
managed expectantly, IUD occurred in 13.2% (95% CI,
7.2–20.5%) and NND in 6.8% (95% CI, 0.7–18.6%) of
fetuses, and 61.9% (95% CI, 38.4–81.9%) of twins had
intact survival. In pregnancies complicated by Type-III
sFGR treated with laser therapy, IUD occurred in 32.9%
(95% CI, 20.9–46.2%) of fetuses and all surviving
twins were without neurological complications. Finally,
in pregnancies with Type-III sFGR treated with selective
reduction, NND occurred in 5.2% (95% CI, 0.8–12.8%)
of cotwins and 98.8% (95% CI, 93.9–99.9%) had intact
survival.
Conclusion Type-I sFGR is characterized by good perina-
tal outcome when managed expectantly, which represents
the most reasonable management strategy for the large
majority of affected cases. Pregnancies complicated
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by Type-II or -III sFGR treated with fetoscopic laser
ablation have a higher rate of mortality but lower rate
of morbidity compared with those managed expectantly,
supporting the use of fetal therapy at gestations remote
from neonatal viability. Data on outcome following selec-
tive reduction are scarce. In view of the lack of evidence
from randomized controlled trials, prenatal management
of sFGR should be individualized according to gestational
age at diagnosis, severity of growth discordance and mag-
nitude of Doppler anomalies. Copyright © 2018 ISUOG.
Published by John Wiley & Sons Ltd.
INTRODUCTION
Selective fetal growth restriction (sFGR) occurs
in 10–15% of monochorionic twin pregnancies
and represents a management challenge1 due to the
interdependence of twins connected via the placental
vasculature. A greater understanding of the relationship
of placental share and vascular structure with the clinical
course and prognosis of sFGR has allowed classification
by umbilical artery (UA) Doppler findings in the smaller
twin2. In Type-I sFGR pregnancy, both twins have normal
end-diastolic flow (EDF) in the UAs, in Type-II there is
absent or reversed EDF and, in Type III, the phenomenon
of intermittently absent or reversed EDF is observed. A
consensus agreement on the diagnostic criteria for sFGR
in monochorionic pregnancy was published recently3, but
clinical uncertainty regarding the optimal management,
particularly in very preterm gestations persists4. The
particular challenge in monochorionic pregnancy is the
risk of acute fetofetal transfusion in the event of demise
or profound hypotension in one twin causing death or
neurological injury in the cotwin. Reported perinatal
survival in pregnancies affected by Type-I sFGR is 97%,
but survival in Types II and III is around 50% and 80%,
respectively4, with a high risk of intrauterine demise that
may be particularly unpredictable in Type-III sFGR5.
Current management options include expectant mon-
itoring with delivery if fetal demise appears imminent,
or active fetal intervention, by either fetoscopic laser
treatment or selective reduction (SR) of the compromised
twin. SR favors the outcome of the larger twin6, while
fetoscopic laser therapy can achieve survival of both twins
in select cases at the cost of a higher risk of mortality and
neurological complications of the larger cotwin7.
The aim of this systematic review was to quantify the
perinatal outcome of twin pregnancies affected by sFGR
according to the type of prenatal management adopted.
METHODS
Protocol, eligibility criteria, information sources
and search
This review was performed according to an a-priori
designed protocol recommended for systematic reviews
and meta-analyses. MEDLINE, EMBASE, CINAHL,
ClinicalTrials.gov and Cochrane Library databases were
searched electronically in February 2018, utilizing
combinations of the relevant medical subject heading
(MeSH) terms, keywords, and word variants for ‘twin
pregnancy’, ‘selective intrauterine growth restriction’ and
‘outcome’ (Table S1). The search and selection criteria
were restricted to the English and French language.
Reference lists of relevant articles and reviews were
hand searched for additional reports. PRISMA8 and
MOOSE9 guidelines were followed. The study was
registered with the PROSPERO database (registration
number: CRD42018087121).
Study selection and data collection
The primary outcome was mortality, including intrauter-
ine death (IUD) of either twin, defined as fetal loss after
20 weeks of pregnancy, not as a result of planned termi-
nation of pregnancy or SR. We collected data on single
IUD, double IUD, neonatal death (NND; defined as death
of either twin up to 28 days postpartum, perinatal death
(PND; defined as IUD or NND), live birth and survival
of at least one twin (up to 28 days).
Secondary outcomes were: (1) overall neonatal morbid-
ity, defined as the presence in either twin of at least one of
abnormal brain imaging, respiratory distress syndrome
(RDS), admission to the neonatal intensive care unit
(NICU) or retinopathy of prematurity; (2) abnormal brain
imaging, defined as the presence of either intraventricular
hemorrhage (IVH) or periventricular leukomalacia (PVL)
of any type on postnatal imaging (ultrasound or mag-
netic resonance imaging); (3) severe IVH (Grade III or
IV); (4) PVL (Grade II or III); (5) RDS; (6) admission to
NICU and (7) intact survival, defined as survival free from
neurological complications.
These outcomes were explored according to type of
sFGR (Type I, II or III), as described by Gratacós et al.2,
management adopted (expectant, fetoscopic laser therapy
or SR) and fetal size (smaller or larger twin). sFGR was
defined as estimated fetal weight (EFW) of one twin
< 3rd centile, or at least two out of four contributory
parameters (EFW of one twin < 10th centile, abdominal
circumference (AC) of one twin < 10th centile, EFW
discordance of ≥ 25%, UA pulsatility index of the
smaller twin > 95th centile) in the absence of ultrasound
signs consistent with the presence of severe twin-to-twin
transfusion syndrome3.
Only studies reporting the incidence of the explored
outcomes in sFGR classified according to Gratacós et al.2
or from which the type of sFGR could be extrapolated
were included. This is justified by the fact that risk
stratification, counseling and management of pregnancies
complicated by sFGR are based upon this classification.
Studies including cases with fetal anomalies were excluded
in view of the higher risk of mortality in the affected
twin. Only full-text articles were considered eligible for
inclusion. Case reports, conference abstracts and case
series with fewer than three cases were excluded to avoid
publication bias. Studies published before 2000 were not
included as advances in diagnosis and management of
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twin pregnancies complicated by sFGR make them less
relevant.
Two authors (F.G.S., R.T.) reviewed all abstracts
independently. Agreement regarding potential relevance
was reached by consensus; full text copies of those papers
were obtained and the same two reviewers independently
extracted relevant data regarding study characteristics and
pregnancy outcomes. Consensus on inconsistencies was
reached by discussion by the reviewers or by discussion
with a third author (F.D.). If more than one study was
published on the same cohort with identical endpoints, the
report containing the most comprehensive information
on the population was included to avoid overlapping
populations. For those articles in which information
was not reported but the methodology was such that
this information would have been recorded initially, the
authors were contacted.
Quality of the included studies was assessed using the
Newcastle–Ottawa Scale (NOS) for case–control studies.
According to NOS, each study is judged on three broad
perspectives: selection of the study groups; comparability
of the groups and ascertainment of the outcome of interest.
Assessment of the selection of a study includes evaluation
of the representativeness of the exposed cohort, selection
of the non-exposed cohort, ascertainment of exposure
and demonstration that the outcome of interest was
not present at the start of study. Assessment of the
comparability of a study includes the evaluation of the
comparability of cohorts based on the design or analysis.
Finally, assessment of ascertainment of the outcome of
interest includes evaluation of the type of assessment
of the outcome of interest and length and adequacy of
follow-up. According to NOS, a study can be awarded
a maximum of four stars within the selection category,
three stars in the outcome category and a maximum of
two stars can be given for comparability10.
Statistical analysis
First, random-effects meta-analysis of proportions was
performed to estimate the pooled rates of each outcome
for each type of sFGR (Type I, II or III) according
to the management reported (expectant, laser or SR).
Second, random-effects head-to-head meta-analysis was
used to compare directly the risk of each outcome among
the smaller vs larger twin, expressing the results as
summary odds ratios and relative 95% CI. Between-study
heterogeneity was explored using the I2 statistic, which
represents the percentage of between-study variation that
is due to heterogeneity rather than chance. A value of 0%
indicates that no heterogeneity is observed, while values
> 50% are associated with substantial heterogeneity.
A random-effects model was ultimately used for all
meta-analyses because of heterogeneity identified between
studies. Potential publication bias was assessed using
Egger’s test and visual inspection of funnel plots. Tests
for funnel plot asymmetry were not used when the total
number of publications included for each outcome was
less than 10, as the tests then lack power to detect
real asymmetry. StatsDirect 3.0.171 (StatsDirect Ltd,
Altrincham) and RevMan 5.3 (The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014) statistical
software was used to analyze the data.
RESULTS
We identified 1859 articles: 61 were assessed with respect
to their eligibility for inclusion and 16 studies were
included in the systematic review (Tables 1 and S2 and
Figure 1). These 16 studies included 786 monochorionic
pregnancies affected by sFGR. The general characteristics
of the included studies are reported in Table 1. There were
no randomized controlled trials comparing the different
management options according to type of sFGR, and all
the included studies were observational. Ten studies11–20
reported outcome following expectant management,
although protocol for expectant management varied
in monitoring and indications for delivery. Not all
studies reported the antenatal management protocols
used for expectantly managed cases11,13,14,20. Outcome
after active management with fetoscopic laser coagulation
was reported by five studies11,13,19,21,22. SR by cord
occlusion was reported in four studies6,11,12,24 and by
radiofrequency ablation in three studies24–26, and these
cases were analyzed together because there was not
likely to be a significant difference between the two
techniques23,24. Several studies reported more than one
management strategy6,11–13,19.
The results of quality assessment of the included studies
using the NOS are reported in Table 2. Most included
studies scored well regarding selection and comparability
of the study groups and ascertainment of the outcome
of interest. The main methodological weaknesses of these
studies were their retrospective design, small sample size,
lack of randomization according to management strategy
and different gestational ages at assessment, intervention
and follow-up.
In view of these limitations, the very small number of
studies reporting each individual outcome and lack of
comparison between the different types of management
in most of the included studies, we decided not to report
the risk comparison for each explored outcome according
to type of management adopted. The included studies
reported a variety of outcomes and no outcome was
reported across all included studies, making it difficult to
compare the relative importance of different outcomes.
For example, the studies that reported double IUD were
not included in the analysis for survival of at least
one twin.
There was also considerable heterogeneity in the
definition of sFGR among the different studies, with
authors variably using EFW, AC and/or degree of fetal
weight discordance (Table 1). We decided to include
articles reporting different definitions provided that the
type of sFGR classified according to Gratacós et al.2 was
reported or could be extrapolated. This choice was based
upon the assumption that the type of umbilical flow
pattern in the smaller twin is the main determinant of
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2019; 53: 36–46.
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Potentially relevant citations identified by searching
MEDLINE (1946–Feb 2018), EMBASE (1947–Feb 2018),
The Cochrane Library (since inception) including CDSR,
DARE and CENTRAL and by manually searching
reference lists
(n = 1859)
Citations retrieved for detailed evaluation
of full manuscript
(n = 61)
Citations excluded (n = 1798)
 • Not relevant (n = 1793)
 • Duplicates (n = 5)
Full-text articles excluded (n = 45)*
 • Conference abstract only (n = 15)
 • Duplicate (n = 2)
 • Wrong outcomes, comparator or
   patient population (n = 12)
 • No English or French full text
 (n = 2)
 • Outcomes not reported according
 to Gratacós classification
 (n = 15)











Figure 1 Flowchart summarizing inclusion in systematic review of
studies on outcome of monochorionic twin pregnancies complicated
by selective fetal growth restriction. *One study had two reasons
for exclusion. †Some studies reported on more than one type of
management. CENTRAL, The Cochrane Central Register of
Controlled Trials; CDSR, The Cochrane Database of Systematic
Reviews; DARE, Database of Abstracts of Reviews of Effects.
Table 2 Quality assessment of included studies on outcome of
monochorionic twin pregnancies complicated by selective fetal
growth restriction, according to Newcastle–Ottawa Scale (NOS)
Reference Selection Comparability Outcome
Gratacós (2004)20   
Gratacós (2008)19   
Ishii (2009)18   
Ishii (2015)21   
Koch (2017)13   
Machado (2014)15   
Panciatici (2017)26  
Parra-Cordero (2016)6   
Pasquini (2015)14   
Peeva (2015)22  
Peng (2016)24  
Quintero (2001)11   
Rustico (2017)12   
Visentin (2013)16   
Wang (2017)25  
Weisz (2011)17   
Only first author of each study is given. Maximum of one star for
each numbered item within selection and outcome categories.
Maximum of two stars can be given for comparability.
perinatal outcome of monochorionic pregnancies affected
by sFGR, irrespective of fetal size or weight discordance2.
Subanalysis according to fetal size was affected by the
very small number of included cases for most outcomes,
which precluded objective risk stratification. The analyses
of pregnancy outcome according to fetal size for those
managed expectantly and those treated using laser therapy
are reported in Tables S3 and S4.
Synthesis of results
The results of the pooled analysis are reported in Table 3.
Figure 2 summarizes the findings for key outcomes. Forest
plots for the analysis of individual outcomes are available
in Figures S1–S3.
Type-I sFGR
There were eight studies (332 twins) on expectant
management in Type-I sFGR11–18, one study (six fetuses)
reporting the outcome of pregnancies complicated by
Type-I sFGR treated with laser therapy of placental
anastomoses11, and two studies (six twins) reporting the
outcome of Type-I sFGR treated with SR of the smaller
twin12,24 (Table 3, Figure 2a).
Overall, single and double IUD occurred in 3.1% (95%
CI, 1.1–5.9%), 2.2% (95% CI, 0.6–4.6%) and 1.9%
(95% CI, 0.6–3.8%) of fetuses in pregnancy complicated
by Type-I sFGR managed expectantly. After laser therapy
in Type-I sFGR, the overall incidence of IUD was 16.7%
(95% CI, 0.4–64.1%) and there was no case of double
IUD. After SR, there were no cases with subsequent
intrauterine death of the larger twin.
Of twins affected by Type-I sFGR managed expectantly,
96.4% (95% CI, 92.6–98.8%) were liveborn, while none
of the reported cases experienced NND. PND occurred
in 3.0% (95% CI, 0.2–8.9%) of fetuses, while all Type-I
pregnancies managed expectantly had at least one twin
that survived to the neonatal period (100%; 95% CI,
94.3–100%). In pregnancies with Type-I sFGR managed
using fetoscopic laser surgery, 83.3% of fetuses (95% CI,
35.9–99.6%) were liveborn and all pregnancies had at
least one twin surviving the neonatal period. In cases in
which SR was used, no perinatal deaths occurred.
Neonatal morbidity occurred in 9.5% (95% CI,
0.5–27.7%) of fetuses in pregnancy complicated by
Type-I sFGR managed expectantly. In those studies
that reported RDS as an outcome, 10.5% (95% CI,
2.9–24.8%) of liveborn fetuses were affected. Abnormal
postnatal brain imaging was observed in 4.1% (95%
CI, 0.04–17.3%), but no cases were reported with the
specific severe brain anomalies on imaging such as IVH
or PVL. None of the included surviving twins of Type-I
sFGR pregnancy managed with laser or SR experienced
morbidity or had abnormal brain imaging after birth.
A detailed description of the different neurological
outcomes reported by each included study is presented in
Table S5. Finally, 79/80 (97.9% (95% CI, 93.6–99.9))
fetuses affected by Type-I sFGR managed expectantly
and all of those managed with laser therapy or SR had
intact survival.
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2019; 53: 36–46.









































































Survival of at least one twin
(c)
Pooled proportion (%)
Figure 2 Results of pooled analysis for key outcomes in pregnancies complicated by Type-I (a) Type-II (b) and Type-III (c) selective fetal
growth restriction, according to management (expectant, ; laser treatment, ; selective reduction, ).
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Five studies (214 twins) reported the incidence of mor-
tality in monochorionic pregnancies affected by Type-II
sFGR managed expectantly12,14–16,18. Three studies (300
twins) reported the outcome of pregnancies complicated
by Type-II sFGR treated with laser therapy of placen-
tal anastomoses13,21,22. Three studies6,12,25 (59 twins)
reported the outcome of Type-II sFGR treated with SR of
the smaller twin (Table 3, Figure 2b).
For Type-II sFGR pregnancies managed expectantly,
overall, single and double IUD occurred in 16.6% (95%
CI, 6.9–29.5%), 8.2% (95% CI, 3.1–15.3%) and 10.4%
(95% CI, 3.6–20.3%) of fetuses, respectively. In contrast,
IUD occurred in 44.3% (95% CI, 22.2–67.7%) of fetuses
in cases managed with laser therapy, all of which were
single IUDs. After SR, IUD of the surviving twin occurred
in 5.0% (95% CI, 0.03–20.5%) of cases.
Of fetuses in Type-II sFGR pregnancies managed expec-
tantly, 81.1% (95% CI, 65.4–92.8%) were liveborn,
while NND occurred in 6.4% (95% CI, 0.2–28.2%) and
PND in 15.0% (95% CI, 3.6–69.5%). Of fetuses in preg-
nancies managed by laser, NND occurred in 15.3% (95%
CI, 2.7–35.7%), and 82.9% (57.8–97.9%) of pregnan-
cies had at least one twin surviving the neonatal period.
After SR, the incidence of NND was 3.7% (95% CI,
0.2–11.1%).
Neonatal morbidity occurred in 25.0% (95% CI,
10.7–44.9%) of fetuses in Type-II sFGR pregnancies
managed expectantly, while 11.8% (95% CI, 0.1–40.9%)
had abnormal postnatal brain imaging. Severe PVL
complicated 11.8% (95% CI, 0.1–40.9%) of twins in
pregnancies managed expectantly, and none experienced
IVH. After expectant management in Type-II sFGR,
75.0% (95% CI, 55.1–89.3%) of twins were admitted
to NICU and 89.3% (95% CI, 71.8–97.7%) survived
without neurological compromise. None of the cases
affected by Type-II sFGR and treated with laser therapy
experienced morbidity or had abnormal brain imaging
after birth, and all twins survived without neurological
complications. After SR, 86.2% (95% CI, 70.5–96.5%)
of cotwins survived the neonatal period and 90.6%
(95% CI, 42.3–94.3%) were free from neurological
complications.
Type-III sFGR
Six studies (170 twins) reported the incidence of mor-
tality in monochorionic pregnancy affected by Type-III
sFGR managed expectantly12,14,15,18–20. Three studies (50
twins) reported the outcome of pregnancy complicated
by Type-III sFGR treated with laser therapy of placen-
tal anastomoses13,19,21. Three studies6,12,26 (52 twins)
reported the outcome of Type-III sFGR treated with SR
of the smaller twin (Table 3, Figure 2c).
Overall, single and double IUD occurred in 13.2%
(95% CI, 7.2–20.5%), 7.2% (95% CI, 3.8–11.5%) and
5.5% (95% CI, 1.2–12.5%) of fetuses, respectively,
in Type-III sFGR pregnancies managed expectantly.
In cases treated with laser therapy, IUD occurred in
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2019; 53: 36–46.
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32.9% (95% CI, 20.9–46.2%) of fetuses: all IUDs
were single. There were no cases of IUD reported after
SR. When stratifying the analysis according to fetal
size, in cases managed expectantly, the incidence of
overall IUD was higher in the smaller (pooled proportion
20.7%; 95% CI, 12.3–30.6%) compared with the larger
(pooled proportion 8.0%; 95% CI, 3.3–14.5%) twin
(P = 0.0267) (Table S3).
After expectant management in Type-III sFGR, 85.1%
(95% CI, 78.5–90.6%) of twins were liveborn, while
NND and PND occurred in 6.8% (95% CI, 0.7–18.6%)
and 22.2% (95% CI, 13.4–32.5%) of fetuses, respec-
tively. There were no NNDs in the group treated
using laser therapy. NND occurred in 5.2% (95% CI,
0.8–12.8%) of fetuses in cases managed by SR. In 87.4%
(95% CI, 73.3–94.8%) of cases managed expectantly,
93.4% (95% CI, 74.3–100%) of those managed with
laser therapy and 80.2% (95% CI, 37.7–100%) of those
managed with antenatal SR, at least one twin survived the
neonatal period.
One study18 (21 twins) found the incidence of neonatal
morbidity of fetuses with Type-III sFGR pregnancies,
when managed expectantly, to be 38.1% (95% CI,
18.1–61.6%). Abnormal brain findings on postnatal
imaging were observed in 20.6% (95% CI, 8.7–37.9%)
of twins in pregnancies managed expectantly, while the
incidence of severe IVH and PVL was 3.5% (95%
CI, 0.4–9.3%) and 11.6% (95% CI, 5.5–19.6%),
respectively. Analysis according to fetal size showed there
was increased rate of morbidity in the larger twin in
Type III cases managed expectantly. Neonatal morbidity
affected 27.3% (95% CI, 6.0–61.0%) of the smaller
twins and 38.5% (95% CI, 13.9–68.4%) of the larger
twins (P = 0.679) (Table S3). Abnormal postnatal brain
imaging was present in 4.1% (95% CI, 0.3–12.0%) of the
smaller twins and 24.7% (95% CI, 14.0–37.3%) of the
larger twins (P = 0.02). Survival free from neurological
complications occurred in 80.0% (95% 44.4–97.5%) of
the smaller twins and 38.5% (95% CI, 13.9–68.4) of the
larger twins (P = 0.09).
Neonatal morbidity was described by two studies (28
twins) reporting the use of laser therapy, with 15.3%
(95% CI, 4.8–30.4%) of fetuses having abnormal brain
imaging after birth19,21. Intact survival at 28 days of age
was reported in all twins of Type-III sFGR pregnancies
managed with laser therapy.
Only one study reporting SR in Type-III sFGR
described neurological morbidity. In this study of two
fetuses, neonatal morbidity occurred in 50% (95% CI,
12.6–98.7%)26, but intact survival was reported in
98.8% (95% CI, 93.9–99.9%) of fetuses in the two
studies reporting this outcome following SR6,26.
DISCUSSION
Summary of main findings
This systematic review confirms that Type-I sFGR
generally has a good perinatal outcome when managed
expectantly, which represents the most reasonable choice
for management. Type-II and -III sFGR pregnancies
treated with laser therapy or SR have a higher rate
of perinatal mortality but a lower rate of morbidity,
compared with those managed expectantly.
Strengths and limitations
The strengths of this review are the thorough
search and assessment of clinical outcomes stratified
by classification and management. The small number
of studies and their retrospective, non-randomized design,
heterogeneous populations and dissimilar management
protocols for sFGR are major limitations. The findings
are also subject to potential publication bias because
the nature of some outcomes and the small number
of studies limit the reliability of formal tests.
Few studies reported gestational age at diagnosis,
although cases classified at 16–18 weeks as Type-II
sFGR may have physiologically rather than pathologically
absent EDF27. Additionally, practice varies in local
availability of fetal intervention, neonatal services and
legal restrictions on termination of pregnancy. In several
centers, expectant management included offering SR for
fetal deterioration < 26 weeks. Furthermore, variation in
outcome reporting precludes meta-analysis of infrequently
reported but important outcomes28. Finally, it was not
possible to explore the association between gestational age
at delivery and neonatal outcome, which is fundamental
because gestational age is the main determinant of
perinatal outcome, irrespective of the severity of sFGR or
Doppler abnormalities29. Despite these limitations, this
study represents the most up-to-date and comprehensive
published estimate on the outcome of sFGR according to
management option.
Clinical and research implications
In the present review, PND was rare in Type-I sFGR
cases, since all pregnancies in studies reporting neonatal
survival had at least one surviving infant and none
had severe neurological morbidity. We identified three
studies (nine pregnancies) reporting fetal therapy in Type-I
sFGR11,12,24. The study by Quintero et al.11 predates the
Gratacós classification and clarity on the prognostic value
of UA Doppler, Rustico et al.12 offered cord occlusion in
cases classified as Type-I sFGR with later deterioration
and Peng et al.24 did not report the indication for SR.
The scarcity of studies reporting intervention in Type-I
sFGR and the growing focus of research on management
of Type-II and -III sFGR point to a developing consensus
that Type-I sFGR should be managed expectantly.
Weekly sonographic and Doppler surveillance is
recommended in expectant management of Type-I sFGR
because disease progression occurs in up to 25%12,
with elective delivery between 34–36 weeks30. Expectant
management of severe sFGR (Types II and III) would
benefit from a clear protocol identifying appropriate
triggers for intervention. Monitoring of Type-III sFGR
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is particularly challenging since IUD is unpredictable
and the risk of neurological injury to the larger twin is
substantial. Known adverse predictors in sFGR include
earlier gestational age at diagnosis, ductus venosus
Z-score31, cord insertion site32,33 and fetal weight
discrepancy34, but further development of prognostic
markers for severe sFGR is needed. In general, severe
sFGR with normal venous Doppler can be managed
expectantly with frequent Doppler, biophysical profile
and cardiotocographic evaluations1.
Type-II sFGR managed with laser therapy is associated
with a higher incidence of fetal loss, but all survivors
were free from neurological morbidity at follow-up,
although it is acknowledged that only small numbers
were available for this analysis. Nonetheless, the finding
that laser therapy appears to reduce neurological
morbidity is consistent with current understanding of
the pathophysiology of sFGR, in which dichorionization
of the placenta is thought to protect the larger twin from
ischemic events. Similarly, since the smaller twin is known
to benefit from vascular anastomoses, dichorionization is
expected to be associated with a higher rate of IUD of the
smaller twin, an observation confirmed on pooled analysis
(Table S3). In the group treated with SR compared
with cases treated with laser therapy, a lower rate of
IUD was observed. This may be explained by technical
difficulties in performing laser therapy in the absence
of polyhydramnios and with amniotic fluid present in
the smaller twin, as well as atypical large vascular
anastomoses. We have found that, when intervention
was reported, clinicians more frequently reported the use
of SR than laser therapy, suggesting a preference for SR
in severe sFGR. Even when laser treatment is preferred, it
might be precluded by technical factors such as placental
site or visibility.
In the present review, 62% of twins in pregnancies
complicated by Type-III sFGR managed expectantly
had intact survival with an observed increase in
neurological injury in the larger compared with in the
smaller twin. After laser treatment, while incidence
of IUD was three-fold higher than that observed
following expectant management, < 16% of survivors had
abnormal brain imaging and all reported survivors were
free from major neurological complications. Likewise,
in pregnancies undergoing SR, there were no cases
of IUD in cotwins and over 98% had intact survival
at follow-up. Fetal therapy may therefore represent a
reasonable approach in Type III cases diagnosed remote
from term.
If fetal therapy is chosen, SR should be the approach
of choice in view of the significant technical difficulties
and surgical complications that can be encountered when
performing fetoscopic laser surgery for sFGR. This is
a challenging recommendation and not feasible when
termination of pregnancy is not an option because of the
legal context or the parents’ preferences. As such, there
is a role for laser therapy and further study is required
to clarify the relative risks of laser therapy compared to
those of SR.
Conclusions
There remains little robust evidence on the optimal
management of pregnancies affected by sFGR. Type-I
sFGR is characterized by a good perinatal outcome
and expectant management is appropriate for most
cases. Type-II and -III sFGR are affected by a higher
burden of perinatal mortality and morbidity. Although
our findings do not support intervention with either
laser therapy or SR, fetal therapy may have a role
at previable gestational ages in severe cases in order to
protect the surviving twin from demise or neurological
damage. Prenatal management of sFGR should be
individualized according to gestational age at diagnosis,
severity of growth restriction and magnitude of Doppler
anomalies. Large multicenter trials sharing objective
protocols of prenatal management and standardized
postnatal follow-up are needed in order to elucidate the
optimal management.
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